Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon5 and 92 bp insertion in exon5.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ATG10, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ATG10 also known as Autophagy-Related Protein 10 is an important player in the autophagy pathway. This protein weighs approximately 21 kDa and is expressed in a variety of tissues with high levels observed in the heart and skeletal muscle. Mechanically ATG10 acts as an E2-like enzyme important for the conjugation of ATG12 to ATG5 forming the ATG12–ATG5 conjugate essential for autophagosome formation.
Biological function summary
The autophagy process involves ATG10 in the covalent attachment of ATG12 to ATG5 a step critical for elongation and completion of autophagosomes. This protein functions as part of the ATG12–ATG5–ATG16L1 complex which plays a structural role in the phagophore membrane. Without ATG10's activity efficient autophagosome assembly cannot occur highlighting its importance in maintaining cellular homeostasis through regulated turnover of cellular components.
Pathways
ATG10 significantly impacts the macroautophagy pathway and links to metabolic control pathways. It interacts closely with proteins such as ATG5 and ATG7 which are necessary for initiating and executing the autophagy process. This involvement ensures the proper degradation of damaged organelles and recycling of nutrients during cellular stress.
Researchers have connected ATG10 activity to conditions like neurodegenerative diseases and cancers. Dysregulation of ATG10 can impair autophagic function which may contribute to Alzheimer's disease progression by preventing the clearance of protein aggregates. Additionally alteration in ATG10 expression has associations with certain cancers where it impacts cancer cell survival and proliferation. Understanding ATG10's interactions with other proteins like BECN1 could further elucidate its role in these diseases.
